Core Viewpoint - NanoViricides, Inc. has received approval from the regulatory agency ACOREP in the Democratic Republic of Congo to start Phase II clinical trials for NV-387, a broad-spectrum antiviral drug aimed at treating MPox disease caused by hMPXV infection [1][2]. Regulatory Approval - The Phase II clinical trial for NV-387 is cleared to proceed, contingent upon the filing of certain documents [2]. - The approval marks a significant milestone in the regulatory development of NV-387, as stated by the company's President and Executive Chairman, Anil R. Diwan [2]. Current Treatment Landscape - There are currently no effective drugs available for treating hMPXV infections that cause MPox disease. A clinical trial for tecovirimat (TPOXX®) failed to show effectiveness over placebo [3]. - Another drug, brincidofovir (TEMBEXA®), is undergoing a clinical trial called "MOSA," but its current status is unknown [3]. MPox Disease Context - MPox Clade II has become endemic in the USA, primarily affecting a limited population of men who have sex with men (MSM) due to transmission during sexual activity [4]. - Recent cases of MPox Clade I in California suggest potential community spread of the virus [5]. NV-387 Drug Profile - NV-387 is designed to mimic human cells, allowing it to trap and destroy viruses, targeting over 90-95% of human pathogenic viruses [6]. - The drug has shown high effectiveness in animal models against various viral infections, including influenza, RSV, and coronaviruses, surpassing existing treatments [10][11]. - NV-387 has demonstrated strong antiviral activity against orthopoxviruses, indicating potential effectiveness against MPox and Smallpox [12]. Development and Future Prospects - The company is compiling required documentation for the Clinical Trial Application, which will be submitted to ACOREP for patient recruitment approval [7][8]. - NV-387 is positioned as a revolutionary treatment for viral diseases, with the potential to address the limitations of current antiviral therapies [15][16]. Company Overview - NanoViricides, Inc. is a clinical-stage company focused on developing nanomaterials for antiviral therapy, with a lead drug candidate NV-387 targeting multiple viral infections, including MPox [17][20]. - The company has a licensing agreement with TheraCour Pharma for the development of antiviral drugs, holding exclusive rights to several technologies [19][22].

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive has bureaus and studios in key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Group 2 - The company is focused on sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] - Proactive adopts technology to enhance workflows and improve content production [4] - All content published by Proactive is edited and authored by humans, ensuring adherence to best practices in content production and search engine optimization [5]

Core Points - NanoViricides, Inc. is a clinical stage company focused on developing broad-spectrum antiviral drugs that are resistant to viral escape [1] - The company will hold its Annual Shareholders Meeting on November 8, 2025, at 10 am in Stamford, Connecticut [1] Company Information - The Annual Shareholders Meeting will take place at Hampton Inn & Suites Stamford, located at 26 Mill River Street, Stamford, CT 06902 [1] - The meeting is an opportunity for shareholders to engage with the company's leadership and discuss future directions [1]

Core Viewpoint - NanoViricides, Inc. is a clinical stage company focused on developing broad-spectrum antiviral drugs that are designed to be effective against viruses without the risk of escape [1] Group 1 - The company will present at the Spartan Capital Investor Conference 2025 in New York City [1] - The presentation is scheduled for November 3, 2025, at 09:45 am ET [1] - The event will take place at the Marriott Marquis Hotel, New York, NY [1]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive has bureaus and studios in key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Group 2 - The company focuses on sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] - Proactive adopts technology to enhance workflows and improve content production [4] - All content published by Proactive is edited and authored by humans, ensuring adherence to best practices in content production and search engine optimization [5]

Core Insights - NanoViricides, Inc. has made significant advancements in its antiviral research, as highlighted by CEO Dr. Anil Diwan in a recent video interview [1] Company Progress - The company is publicly traded on NYSE American under the ticker NNVC [1] - Dr. Anil Diwan discussed the major progress in the company's antiviral research during the interview with Steve Darling from Proactive [1]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team operates from key finance and investing hubs, including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Expertise and Focus Areas - The company specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive delivers news and insights across various sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is committed to adopting technology to enhance its content creation and workflow processes [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans [5]

Core Insights - NanoViricides, Inc. announced that its clinical lead drug NV-387 has demonstrated strong activity against the Measles virus in both cell culture studies and a humanized animal model [1] - The treatment with NV-387 resulted in the protection of lungs, which is crucial for the survival of severely ill patients during late-stage viral infections [1] Company Summary - NanoViricides, Inc. is a publicly traded company listed on NYSE Amer under the ticker NNVC [1] - The company is focused on developing antiviral therapies, with NV-387 being a significant part of its clinical pipeline [1]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Insights - NanoViricides, Inc. announced that its clinical lead drug NV-387 has demonstrated strong efficacy against the Measles virus in a humanized animal model [1] - The company is preparing to make NV-387 available for emergency use application in response to ongoing Measles outbreaks [1] Company Summary - NanoViricides, Inc. is a publicly traded company listed on NYSE American under the ticker NNVC [1] - The company focuses on developing antiviral therapies, with NV-387 being a significant advancement in its pipeline [1] Industry Context - The announcement comes amid a rising number of Measles outbreaks, highlighting the urgent need for effective treatments [1] - The potential emergency use of NV-387 could position the company as a key player in addressing public health challenges related to viral infections [1]